Evidence map›Paper›PMID 35679010›Full record

ReviewDiabetes therapy : research, treatment and education of diabetes and related disorders2022

Management of Diabetes and Hypertension within the Gulf Region: Updates on Treatment Practices and Therapies.

Mohamed Hassanein, Mousa A J Akbar, Mostafa Al-Shamiri, Ashraf Amir, Aslam Amod, Richard Chudleigh, Tarik Elhadd, Hussien Heshmat, Mahdi Jibani, Yousef M Al Saleh

Open access · goldAbstract readReview
In one paragraph

Review in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 7 countries.

Mohamed HassaneinEndocrine Department, Dubai Hospital/Dubai Health Authority, Alkhaleej Road, PO Box 7272, Dubai, United Arab Emirates. mhassanein148@hotmail.com.ORCID http://orcid.org/0000-0001-6598-6972
Mousa A J AkbarALSABAH Hospital, Ministry of Health, Kuwait City, Kuwait.
Mostafa Al-ShamiriCardiac Sciences Department, Medical College, King Saud University, Riyadh, Saudi Arabia.
Ashraf AmirInternational Medical Center Hospital (IMC), Jeddah, Saudi Arabia.
Aslam AmodNelson R. Mandela School of Medicine & Life Chatsmed Garden Hospital, Durban, South Africa.
Richard ChudleighSwansea University Medical School, Swansea, Wales, UK.
Tarik ElhaddHamad Medical Corporation (HMC), Doha, Qatar.
Hussien HeshmatCardiology Department, Cairo University, Cairo, Egypt.
Mahdi JibaniGwynedd Hospital, Bangor, North Wales, UK.
Yousef M Al SalehCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, 22490, Saudi Arabia.
Cairo University · EGDubai Health Authority · AEHamad Medical Corporation · QAKing Abdullah International Medical Research Center · SAKing Saud bin Abdulaziz University for Health Sciences · SAKing Saud University · SAMinistry of Health · KWNelson Mandela Academic Hospital · ZASwansea University · GBYsbyty Gwynedd Hospital NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disease (CVD) is a leading cause of death globally, driven by the high rates of risk factors, such as diabetes and hypertension. As the prevalence of these risk factors is particularly high in the Gulf region, better diagnosis and management of type 2 diabetes (T2D) and hypertension has the potential to dramatically reduce adverse cardiovascular outcomes for individuals in that part of the world. This article provides a summary of presentations made during the EVIDENT summit, a virtual symposium on Evidence in Diabetes and Hypertension, held in September 2021, including a review of the various guidelines for both T2D and hypertension, as well as recent findings relevant to the safety and efficacy for therapies relating to these conditions. Of relevance to the Gulf region, the risk of hypoglycaemia with sulfonylureas during Ramadan was reviewed. For the management of T2D, sulfonylureas have been a long-standing medication used to achieve glycaemic control; however, differences have emerged between early and later generations, with recent studies suggesting improvements in the safety profiles of late-generation sulfonylureas. For patients with hypertension, incremental therapy changes are recommended to reduce the risk of cardiovascular complications that are associated with increasing blood pressure. For first-line therapy, angiotensin-converting enzyme inhibitors (ACEi), such as perindopril, have been demonstrated to reduce the risk of cardiovascular and all-cause mortality. The addition of calcium channel blockers and diuretics to ACEi has been shown to be effective in patients with poorly controlled hypertension. The different renin-angiotensin-aldosterone system inhibitors are reviewed, and the benefit of combination therapies, including amlodipine and indapamide in patients with difficult-to-control hypertension, is investigated. The benefits of lifestyle modifications for these patients are also discussed, with important clinical considerations that are expected to inform patient management in daily clinical practice.

Indexed as

AmlodipineGliclazide MRGuidelinesHypertensionIndapamidePerindoprilRamadanSulfonylureasType 2 diabetes

Identifiers

PMID35679010
PMCPMC9178531
OpenAlexW4281824034

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.